护肝宁片治疗非酒精性脂肪性肝炎的实验研究

目的探讨护肝宁片对大鼠非酒精性脂肪性肝炎的治疗作用及机制。方法雄性SD大鼠39只，正常喂养1周后按体质量层次随机分为正常对照组（n=9）和实验组（n=30），正常对照组予标准饮食，实验组予高脂饮食。11周末验证造模成功后，将余下25只实验组大鼠再分为：高脂组、饮食治疗组，及护肝宁高剂量组、中剂量组、低剂量组。分别给予高剂量、中剂量、低剂量护肝宁片灌胃及标准饮食。16周末处死大鼠，检测肝指数、体脂比、血清ALT、AST、TC、TG、LDL．C、血糖、超氧化物歧化酶（SOD）、丙二醛，并行肝组织病理检查及肝匀浆TC，TG，LDL—C和丙二醛测定。结果护肝宁中剂量组、护肝宁低剂量组体脂比分别为（3．08±0．49）％与（3．07±0．82）％]较饮食治疗组及高脂组降低（P〈0．05）；护肝宁高剂量组血清AST水平、TC水平、血糖水平及肝匀浆11c水平分别为（119．8±14．7）U／L、（1．59±0．38）mmo]／L、（5．44±0．44）mmol／L及（0．34±0．07）mmol／L]明显低于饮食治疗组，护肝宁高剂量组血清SOD水平（47．38±5．72）％]明显高于饮食治疗组（P〈0．05）；护肝宁高剂量组较饮食治疗组及高脂组肝组织的脂肪变程度、炎症程度和纤维化程度均明显减轻（P〈0．05）。结论护肝宁片可有效治疗大鼠非酒精性脂肪性肝炎。

Effect of Huganning tablet on nonalcoholic steatohepatitis in rats

Objective To investigate the protective effect and mechanism of Huganning tablet on rat model of nonalcoholic steatohepatitis( NASH). Methods After one week of a standard diet 39 male SD rats were random-ly divided into the normal control group(n =9) and the experimental group(n =30). The normal control group rats were fed with a standard diet, while those of the experimental group had a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly sub-divided into five groups :Group Z(n =5) with a high-fat diet and gastric with saline, GroupY(n=5) with a stand-ard diet and gastric with saline, GroupA(n=5), Group B(n=5) and Group C(n =5) with a standard diet and gastrically infused with the Huganning Tablet solution of high-dosage (700 mg/kg/d), middle-dosage (350 mg/kg/d) and low-dosage(175 mg/kg/d), respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum ALT, AST,TG,TC, LDL-C, GLU, SOD and MDA. Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDL-C and MDA levels. Results There were lower levels of visceral adiposity ratio in Group B and Group C compared with Group Y( P <0. 05 ). There were low-er levels of serum AST, TC, GLU and liver tissue TC in Group A compared to Group Y(P<0.05). A significant increase was found in the serum SOD levels in Group A compared to Group Y( P < 0. 05). A significant reduction was observed in Group A in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z ( P < 0. 05). Conclusions Huganning Tablet seems to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.